South Dakota Investment Council Nektar Therapeutics Transaction History

South Dakota Investment Council

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$3.17 - $6.17 $95,296 - $185,482	-30,062 Closed	0 $0
Q1 2021 May 13, 2021	BUY	$16.56 - $25.46 $497,826 - $765,378	30,062 New	30,062 $601,000
Q2 2019 Aug 13, 2019	SELL	$31.0 - $36.3 $145,700 - $170,610	-4,700 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$46.46 - $68.49 $18,584 - $27,395	-400 Reduced 7.84%	4,700 $287,000
Q2 2018 Aug 13, 2018	BUY	$46.25 - $104.45 $235,875 - $532,695	5,100 New	5,100 $249,000

146

139M

32.6K

14.1K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $174M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of South Dakota Investment Council, based on Form 13F filings with the SEC.

Stay updated on South Dakota Investment Council with notifications on news.